These findings were recently supported by the use of an organoid biobank derived from patients with colorectal cancer, in which organoids with RSPO fusions or RNF43 mutations exhibited lower AXIN2 expression than APC-mutant organoids [58]. This evidence concerns the gene AXIN2 and colorectal cancer.